Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 37

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 37
---
 2025, following our notification to the Purchasers that all                                                                                                                                                 
 material conditions for the closing of the Kineta Merger have been satisfied (other than conditions that cannot be satisfied until on or immediately before the closing of the Kineta Merger) and that we were prepared to close the Kineta Merger. |

In addition to the approximately $8.9 million that was purchased in four tranches through July 24, 2025, under the Securities Purchase Agreement, approximately $3.7 million of the Private Placement (the “Final Tranche Private Placement Amount”) was required under the Securities Purchase Agreement to be purchased and funded by December 31, 2025 by four Purchasers who had the right defer the purchase of a portion of their Common Stock and Private Placement Warrants until such time (the “Deferral Investors”). The Deferral Investors were Pranabio Investments LLC, Garden Street House, LLC, Thomas C. Mollick, and Matthew Nachtrab. On September 5, 2025, each of Deferral Investors and us entered into an agreement (the “Final Purchase Agreements”) pursuant to which they agreed to immediately purchase an aggregate of $3.2 million of the Final Tranche Private Placement Amount in exchange for our agreement, set forth in a Warrant Amendment Agreement between us and each Deferral Investor (the “Warrant Amendment Agreements”), to extend the expiration dates of certain warrants to purchase an aggregate of 1.5 million shares of Common Stock that were issued by our predecessor in a 2024 private placement of convertible notes (the “2024 Warrants”). Under the Warrant Amendment Agreements, the expiration dates of the 2024 Warrants were extended to December 31, 2030. We currently plan to use the net proceeds from the Private Placement for cash requirements to fund expenses acquired in connection with the Kineta Merger, to fund the initiation of the Phase 3 Trial for IFx-2.0,to fund the advancement of TBS-2025to a Phase 2 trial and for other working capital needs. 26

The Private Placement Warrants have an exercise price per share equal to $3.3125 and will expire on December 3, 2030. The exercise price of the Private Placement Warrants is subject to proportional adjustment for stock splits, reverse stock splits, and similar transactions. The shares of Common Stock, Private Placement Warrants and the shares of Common Stock issuable upon exercise of the Private Placement Warrants were issued